OSR Holdings Inc. (NASDAQ:OSRH) shares surged 41.28% to $0.65 in after-hours trading on Wednesday after announcing a global exclusive license agreement with Switzerland-based life sciences investment entity BCM Europe AG for its Phase 3-ready oral cancer immunotherapy, VXM01.
What’s The Deal Structure?
Under the deal, BCME, OSRH’s largest shareholder, gains exclusive rights to develop, manufacture, commercialize and sublicense VXM01. OSRH stands to collect up to $815 million in milestone payments tied to clinical, regulatory and commercial benchmarks, plus 100% of downstream royalties after BCME recoups its investment.
OSRH will also acquire full VXM01 intellectual property from biotechnology company Vaximm AG via a $30 million asset purchase.
BCME and its affiliates have pledged their entire approximately 29.7% OSRH stake as collateral for milestone obligations.
CEO Peter Hwang said, “It ensures OSR Holdings shareholders participate directly in value creation, while BCME remains accountable for its financial commitments.”
data-variant=”card”
…
